qEEG biomarkers demonstrated anxiolytic efficacy in both Phase 1 of GRX-917 and Phase 1 of etifoxine.
- qEEG Beta power increase
- Rapid-onset, sustained activity
- Time-dependent
- Exposure-dependent
- Increased qEEG Beta Power PD marker confirms
- GABAA receptor target engagement
- Anxiolytic efficacy biomarker
For questions contact:
Richard G. Farrell
Chief Financial Officer
Follow us on LinkedIn
We post current progress and developments on our GABA Therapeutics’ LinkedIn page. Click here to follow us LinkedIn.
